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Abstract
Objective—Experiments in animal models have shown a positive association between in utero 
exposure to pharmacologic sex hormones and offspring obesity. The developmental effects of 
such hormones on human obesity are unknown.
Methods—Using data from a large, prospective pregnancy cohort study (n=19,652), with linkage 
to a national prescription registry, we evaluated the association between use of hormonal 
contraceptives before and after conception (defined from dispensed prescription data and 
characterized by last date of use relative to conception, 12 – >4 months before (n=3,392), 4 – >1 
months before (n=2,541), 1 – > 0 months before (n=2,997), and 0–12 weeks after (n=567)) in 
relation to offspring overweight or obesity at age 3 years.
Results—We observed a weak, inverse association between early pregnancy use of a 
combination oral contraceptive and offspring overweight or obesity at age 3 (adjusted OR: 0.75, 
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95% CI: 0.53, 1.08) and a positive, but imprecise, association with use of a progestin-only oral 
contraceptive in early pregnancy (adjusted OR: 1.26, 95% CI: 0.79, 2.02). In general, no 
association was observed between use of a hormonal contraceptive before conception and 
offspring overweight or obesity. A sensitivity analysis comparing combination oral contraceptive 
users in early pregnancy to other unplanned pregnancies without hormonal contraceptive use 
further strengthened the inverse association (adjusted OR: 0.70, 95% CI: 0.48, 1.02). Other 
sensitivity analyses were conducted to evaluate the robustness of the associations observed given 
varying assumptions.
Conclusion—Pharmacologic sex hormones in early pregnancy may be inversely or positively 
associated with offspring overweight or obesity at age 3, depending on the specific formulation 
used. The present study provides support for the potential for environmental sources of 
hormonally active agents to exert developmental effects.
Keywords
Hormonal contraceptives; Estrogen-mimicking compounds; Pediatric overweight and obesity; 
Developmental origins of health and disease; The Norwegian mother and child (MoBa) cohort 
study
Introduction
Worldwide, the prevalence of childhood overweight and obesity increased from 4.2 percent 
in 1990 to 6.7 percent in 2010.1 Children who are overweight or obese are more likely to be 
overweight in adulthood and to suffer from obesity-related morbidity and mortality.2, 3 The 
obesity epidemic has been primarily attributed to changes in dietary and physical activity 
behaviors,4, 5 but exposure to estrogen-mimicking compounds during developmentally 
sensitive periods may contribute.6, 7
Estrogenic agents can affect adipogenesis in vitro. 17-β estradiol has resulted in increased 
preadipocyte proliferation, likely though up-regulation of PPAR-γ.8 Preadipocyte formation 
can occur as early as the blastocyst stage,9 although upregulation of mesenchymal stem cell 
recruitment to preadipocytes is highest in the second trimester of pregnancy.10
In a previous study of the association between oral contraceptive (OC) and diethylstilbestrol 
(DES) use in pregnancy and offspring obesity,11 the strongest magnitude of association for 
OCs was in months 1 and 2 and, for DES, in months 3–4. This study was executed at a time 
when the potency of OCs was considerably stronger (1959–1974).
Experiments in animal models have shown a positive association between in utero and 
neonatal exogenous estrogen exposure and metabolic disruption in the offspring, including 
offspring overweight or obesity.6, 7 However, in utero exposure to androgens has also been 
associated with offspring obesity.12–14 Hormonal contraceptives can be androgenic, 
depending on the progestin component included.15 The developmental effects of exogenous 
sex hormones on growth may be sex-dependent, with associations primarily in male 
offspring.16
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The maternal metabolic milieu is also associated with offspring overweight or obesity.17, 18 
Hormonal contraceptives have, for many women, unintended metabolic effects, including 
elevated levels of very low-density lipoprotein cholesterol and total triglycerides.15, 19–21 
Hormonal contraceptives increase plasma insulin and cortisol,21 and induce a state of insulin 
resistance.15, 19, 20 Some of these metabolic changes, including increased total cholesterol22 
and insulin resistance,23 are similar to those in women who are overweight or obese.. 
Whether these metabolic effects persist after cessation of use is unclear; however more 
androgenic formulations may subsequently increase risk of gestational diabetes.24
The half-lives of hormonal contraceptives are generally <24 hours;25 however in some 
instances drug components may be detectable for several months post cessation. For 
example, Medroxyprogesterone Acetate has been detectable in serum at 8 months post 
cessation of administration.15 Previous hormonal contraceptive use may have long-term 
effects on endogenous hormone levels, including altered hormone levels both during 
pregnancy26 and after menopause.27
Given the data suggesting that hormonal compounds cause changes in follicular,28, 29 
embryonic, and fetal development,30, 31 that they may cause an obesity-like metabolic 
milieu,32 and that they may exert long-term effects on endogenous sex hormone levels,27, 33 
additional studies of hormonal contraceptive exposure and offspring development in humans 
are needed.
Because use of pharmacologic sex hormones in early pregnancy is relatively uncommon, 
most cohort studies lack the power to evaluate the association. Hormonal contraceptive 
failure occurs in about 3% of users.34 With over 40,000 children followed to age 3, the 
Norwegian Mother and Child Cohort Study (MoBa)35 offers an unusual opportunity to 
assess the influence of in utero exposure to exogenous sex hormones, through hormonal 
contraceptive use in early pregnancy, on childhood overweight or obesity. In the present 
study, through linkage of MoBa data with the Norwegian Prescription Registry (NorPD), we 
evaluated the association between hormonal contraceptive use and offspring overweight or 
obesity at 36 months of age.
Methods
MoBa study participants were recruited in Norway from 1999 through 2008, as described in 
detail elsewhere.35 Women were identified for eligibility when scheduling the routine 
prenatal ultrasound offered free of charge to all pregnant women in Norway at 17–20 weeks 
of gestation. Women were mailed an invitation to participate before the scheduled 
ultrasound, with informed consent and enrollment taking place at the ultrasound 
examination. Approximately 42 percent of all pregnant women in Norway were invited to 
participate in the study. Of these, 39 percent consented to participate. At enrollment, 
participants were asked to complete a self-administered questionnaire to collect data on 
demographic characteristics, reproductive health history, disease and medication history, 
lifestyle factors, and socioeconomic status. Follow-up is conducted through self-
administered questionnaires.
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Prescription data from NorPD contains individual-level data on all medications prescribed 
and dispensed through pharmacies to non-institutionalized individuals in Norway. By 
Norwegian law, as of January 1, 2004, all pharmacies must provide electronic data for all 
prescriptions dispensed. Data quality measures are in place for assuring the NorPD is 
accurate and complete.36 A validation study of hormonal contraceptive use in the NorPD 
was conducted in adolescents and indicated a sensitivity of 99% and a specificity of 76% for 
the NorPD as compared to self-reported use.37 In adolescents, hormonal contraceptives may 
be provided at no cost to the individual, but in adults, hormonal contraceptives are not a 
reimbursable prescription. This may increase the likelihood that a dispensed prescription 
will be used by the individual.
There were 107,308 MoBa pregnancies registered in the Medical Birth Registry of Norway 
(MBRN). All MBRN data are collected on a standardized birth notification form completed 
by the midwife or physician attending the birth. For the present analysis, we included 
pregnancies resulting in a singleton live birth, with no record of death in the first year of life, 
and with no documentation, on either the MoBa 17-week questionnaire or the MBRN, of 
having received infertility treatment for the index pregnancy. We additionally excluded 
pregnancies to women with pre-pregnancy chronic hypertension (n=527). As the NorPD 
registry was not initiated until January 1, 2004, we further restricted our study population to 
pregnancies of women enrolled at least 12 months after the date on which the NorPD 
registry began collection of data (n=48,615). For the primary analyses, we also excluded 
pregnancies with missing covariate data (n=3,966), and for loss to follow-up at age 3 
(n=24,997). The final study population included 19,652 pregnancies to 18,759 women 
(17,867 women with 1 offspring in the cohort, 1,782 with 2, and 1 with 3 offspring) (Figure 
1). The University of North Carolina at Chapel Hill, the National Institute of Environmental 
Health Sciences Institutional Review Board, and the Norwegian Southeastern Regional 
Ethics Committee reviewed and approved this study.
Hormonal contraceptive use, before conception and in early pregnancy, was characterized 
according to the Anatomical Therapeutic Chemical (ATC) Classification System.38 We 
characterized exposure by type and route of administration (combination OC, progestin-only 
OC, vaginal ring, transdermal, injectable, implant, and hormonal-based intrauterine device) 
and by progestin formulation. All hormonal contraceptives with an estrogen component 
(combination OC, vaginal ring, and the transdermal contraceptive) contained ethinyl 
estradiol, but there were eight different progestin types used solely or in combination with 
ethinyl estradiol, including desogestrel, drospirenone, levonorgestrel, norelgestromin, 
norethisterone, lynestronol, medroxyprogesterone, and etonogestrel. Any exposures with 
fewer than 10 exposed cases we combined into a single “other” category (Supplementary 
Table S1).
Although our primary interest was to explore the association between exposure in early 
pregnancy and offspring overweight or obesity, we also characterized exposure into discrete 
windows of hormonal contraceptive exposure according to last date of use relative to 
conception, e.g. 12 – >4 months before, 4 – >1 months before, 1 – > 0 months before, and 
0–12 weeks after. These periods of exposure were selected as they correspond to possibly 
distinct developmental periods of susceptibility, specifically the primordial follicular phase 
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(FSH independent) (12 to 4 months before conception), the secondary to antral phase of 
follicular development (FSH dependent) (4 to 1 month before conception), the emergence of 
a dominant follicle and release of the oocyte (1 month before conception), and post 
conception, early pregnancy (weeks 0–12), when endogenous levels of estradiol and 
progesterone are still relatively low and exogenous sources of exposure may contribute a 
relatively higher dose (relative to endogenous levels).39
Date of conception was estimated by subtracting 17 days40 from the number of days of 
gestational length at birth (to account for the follicular phase prior to conception) and then 
subtracting this value from the date of birth. We used the last menstrual period (LMP)-based 
estimated gestational length unless the LMP-based gestational length was missing (5.1%) or 
≥2 weeks from the ultrasound-based estimate of gestational length (5.2%), in which case we 
used the ultrasound based measure.41 We then constructed an exposure window for each 
hormonal contraceptive prescription filled using the date that the prescription was filled and 
the number of defined daily doses dispensed (day’s supply). Most OCs were dispensed in a 
3 month supply (82%) or a 6 month supply (15%). For pregnancies with more than one type 
of hormonal contraceptive prescribed, we assigned exposure type according to the type of 
contraceptive used closest to the estimated date of conception. Because many women may 
choose to stop taking their hormonal contraceptive in order to achieve conception, we 
characterized women as exposed in early pregnancy only if they reported that the pregnancy 
was unplanned and had ≥ 1 day supply of hormonal contraceptive at or after the day of 
conception.
Offspring overweight or obesity was defined by first calculating the offspring body mass 
index (BMI) (kg/m2) at age 3 years from questionnaire-reported height and weight 
measures. In Norway, families are provided a health card to record information about their 
children. Mothers were asked to transcribe the health care data on height, weight, and date 
onto a MoBa questionnaire when the children were three years old. Offspring were 
characterized as overweight or obese using the age- and sex-specific cut points developed by 
the International Obesity Taskforce (IOTF) (17.89 kg/m2 for boys and 17.56 kg/m2 for 
girls).42 To evaluate the accuracy of the child height and weight data, we conducted a 
validation substudy. We assessed the correlation between BMI obtained from the 
questionnaire and BMI based on measures taken for the Bergen Growth Study.43 The 
correlation was examined among measures obtained within 90 days of one another.44
Covariate selection was informed through construction of a directed acyclic graph.45 The 
adjustment factors selected (and data source) were maternal age (MBRN) (14–19, 20–29, 
30–39, 40–49), prepregnancy BMI (MoBa pregnancy questionnaire) (kg/m2)(<18.5, 18.5–
24.9, ≥25.0), parity (MBRN) (0, 1, ≥2), smoking (composite from MoBa questionnaires and 
the MBRN) (none, quit during pregnancy, smoker), and education (MoBa pregnancy 
questionnaire) (>4 years of university or technical, 4 year university or technical degree, 3 
years of college preparatory high school, 3 years of technical high school, 1–2 years of high 
school, <9 years of secondary school, other).
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Our primary analyses were concerned with assessing the association between early 
pregnancy hormonal contraceptive exposure, as compared to no use of a hormonal 
contraceptive in early pregnancy or the 12 months before pregnancy, and offspring 
overweight or obesity. We used generalized linear models with a logit link, and generalized 
estimation equations (GEE) with an independent correlation matrix46 to estimate robust 
standard errors and account for lack of independence between siblings. We used similar 
models to assess the association between hormonal contraceptive use prior to conception 
and offspring overweight or obesity. Finally, we evaluated the association between 
hormonal contraceptive use with BMI z-score, calculated from the World Health 
Organization growth standards for BMI.47
Subgroup analyses
In subgroup analyses, we explored the association between route of administration and type 
of progestin agent and offspring overweight or obesity. We also explored whether there was 
evidence of interaction between hormonal contraceptive use and offspring sex, maternal 
prepregnancy overweight/obese status (≥25.0 kg/m2; Yes/No), or maternal pre-pregnancy 
weight using interaction terms. A priori, we considered a p value <0.20 as evidence of 
potential interaction.48 Given evidence of possible interaction, we examined stratum-
specific estimates. All analyses were conducted using SAS v9.3 (SAS Inc., Cary, North 
Carolina).
Sensitivity analyses
We conducted several sensitivity analyses to address the potential for residual confounding 
or confounding by indication (use of different comparator groups and additional adjustment 
factors), the potential for selection bias from loss to follow-up (use of both multiple 
imputation and inverse probability weighting), and the potential for exposure 
misclassification (consideration of self-reported use of hormonal contraceptives). We also 
assessed whether a log-binomial model, for estimating relative risks, generated estimates 
that were materially different from estimates obtained in the logit model estimating odds 
ratios. The methods for these analyses are described in Supplement I, with supporting details 
provided in Supplementary Tables S1–S3.
Results
In general, compared to all MoBa pregnancies with baseline data collected in pregnancy and 
at birth, the pregnancies included in the final study sample were to women who were older, 
less parous, more educated, and less likely to have smoked in pregnancy (Table 1). At 36 
months of age, 2,653 (13.1%) children in the analysis met the IOTF definitions for 
overweight or obese. We identified 3,392 pregnancies exposed 12 – >4 months before, 2,541 
4 – >1 months before, 2,997 1 – >0 month before, and 567 0 – 12 weeks after conception. 
For the validation substudy, 77 children had height and weight data at age 3 collected in 
both MoBa and the Bergen Growth study. These data were obtained no more than 90 days 
apart from the respective studies (mean difference: 32 days, std 33 days). The correlation of 
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BMI between the two sources of data was high (Pearson r=0.86, 95% CI: 0.81, 0.90) and 
consistent with the expected correlation between BMI calculated from serial measures of 
height and weight in young children.44
Primary analyses
In early pregnancy, the combination OC was weakly, inversely associated with offspring 
overweight or obesity at age 3 (aOR: 0.75, 95% CI: 0.53, 1.08). The progestin-only OC was 
weakly, positively associated with overweight or obesity (aOR: 1.26, 95% CI: 0.79, 2.02) 
(Table 2). Use of a hormonal contraceptive before pregnancy was generally not associated 
with overweight or obesity, with the exception of use of a vaginal ring-type hormonal 
contraceptive, which was inversely associated, particularly for exposure estimated to have 
occurred 1 – >0 months before conception (aOR: 0.60, 95% CI: 0.35, 1.04) (Table 2). Data 
were too sparse to evaluate the association between early pregnancy use of the vaginal ring 
and subsequent offspring overweight or obesity. The direction of the estimates obtained 
when modeling BMI z-score as a continuous outcome were similar to those obtained when 
modeling BMI as a dichotomous outcome (data not shown).
Subgroup analyses
Among combination OC users, the association with overweight or obesity was similar across 
combination OCs with differing progestin components (Supplementary Tables S4–S7). In 
early pregnancy only, the desogestrel progestin-only OC was moderately associated with 
offspring overweight or obesity (aOR: 1.87, 95% CI: 1.06, 3.32) (Supplementary Table S4).
For early pregnancy use of a combination OC there was weak evidence of effect 
modification by offspring sex or maternal pre-pregnancy BMI. For exposure to the 
combination OC in early pregnancy, the observed association with overweight or obesity 
was present only in males (aOR: 0.56, 95% CI: 0.32, 0.97 in males vs aOR: 0.98, 95% CI: 
0.63, 1.53 in females). The magnitude of association observed for use of the combination 
OC was also stronger in women characterized as normal BMI (BMI <25.0 kg/m2) (aOR: 
0.64, 95% CI: 0.40, 1.02 in normal BMI women vs aOR: 0.95, 95% CI: 0.56, 1.62 in 
overweight or obese women), although confidence intervals of the strata overlapped 
considerably (Supplementary Table S8). There was no evidence of interaction between 
hormonal contraceptive use (of any type) and maternal pre-pregnancy weight (p for 
interaction term >0.20).
Sensitivity analyses
In early pregnancy, for the analyses evaluating the use of different comparator groups, the 
inverse association between the combination OC and offspring overweight or obesity was 
robust to restricting the comparator population to unplanned pregnancies (aOR: 0.70, 95% 
CI: 0.48, 1.02) (Table 3). This inverse relationship was also materially unchanged when 
comparing early pregnancy combination OC users to former users of the combination oral 
contraceptive and when comparing the combination OC users to the progestin-only OC 
users (aOR: 0.75, 95% CI: 0.52, 1.06) (Table 3). Similarly, the relationship between 
Jensen et al. Page 7













progestin use in early pregnancy and offspring overweight or obesity was robust to choice of 
comparator groups (Table 3).
The estimate comparing vaginal ring use to the combination OC (within 1 month prior to 
conception) was aOR 0.59 (95% CI: 0.33, 1.03) and consistent with estimates obtained when 
comparing vaginal ring users to non-users of a hormonal contraceptive (aOR: 0.60, 95% CI: 
0.35, 1.04).
The magnitude of the estimates from models employing multiple imputation were somewhat 
attenuated (aOR: 0.85, 95% CI: 0.66, 1.11 for the combination OC) compared to those 
obtained in the primary analyses (aOR: 0.75, 95% CI: 0.53, 1.06) while estimates obtained 
using inverse probability weighting were somewhat strengthened (aOR: 0.68, 95% CI: 0.49, 
0.99 for the combination OC) (Supplementary Tables S9–S10). Characterizing exposure by 
self-reported use in early pregnancy, as reported on the questionnaire administered during 
pregnancy, also attenuated the estimates observed and introduced additional imprecision 
(aOR: 0.88, 95% CI: 0.57, 1.35 for use of the combination OC and aOR 1.15, 95% CI 0.58, 
2.28 for use of the progestin-only OC) (data not shown). Adjustment for diabetes type I or 
II, age in 5-year increments, income, and maternal weight did not substantively change the 
estimates (data not shown). Estimates obtained using a log-binomial model were also not 
materially different (Combination OC RR: 0.78 (95% CI: 0.57, 1.82) and Progestin-only OC 
RR: 1.23 (95% CI: 0.83, 1.82) for early pregnancy use).
Discussion
In our primary analysis of the association between early pregnancy hormonal contraceptive 
use and offspring overweight or obesity, we found that use of a combination OC was 
weakly, inversely associated with offspring overweight or obesity at age 3. Use of the 
progestin-only OC in early pregnancy was weakly, positively associated with offspring 
overweight or obesity. A moderate positive association for early pregnancy progestin-only 
OC use was observed for desogestrel. With the exception of an inverse association for the 
vaginal ring, there was no association with use of a hormonal contraceptive before 
pregnancy and offspring overweight or obesity. The absence of an association with use 
before pregnancy suggests that any developmental effect may be result of a direct effect on 
the embryo and fetus, as opposed to changes to follicular or oocyte development. The 
relevance of timing of use was further supported by an evaluation of self-reported duration 
which was unrelated to offspring overweight or obesity (data not shown).
All of the associations were qualitatively unchanged with selection of different comparator 
groups, suggesting that the characteristics of women using the contraceptive were not 
contributing to the estimates observed. The sensitivity analyses indicated that the results 
could have been affected somewhat by out-selection bias, but the direction of the bias was 
unclear. The sensitivity analyses also showed results were attenuated when based on self-
reported hormonal contraceptive use. Self-reported data, however, lacked the detail of the 
NorPD data, and progestin specific associations could not be ascertained.
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In experimental animal models, in utero and neonatal exposure to estrogenic agents (DES 
and 17β-estradiol) results in an initial period of depressed growth, followed by increasing 
adiposity at follow-up.6,16 Although the timing of exposure for these animal studies is 
somewhat different (from conception through birth for pregnancy and in early neonatal life), 
the weak, inverse association with the combination pill in the present study may be 
congruent with observations of an initial period of depressed growth in these experimental 
studies. The evidence for depressed growth from hormonal contraceptives in human studies 
has been mixed, with some studies indicating no association with birthweight or low-birth-
weight and others indicating a weak, positive association with low-birth-weight. The number 
of exposed pregnancies in these studies has been small and unable to differentiate between 
contraceptive formulations.49–52 Additional follow-up of the MoBa cohort will allow 
investigation of associations at later ages to determine whether the growth pattern exhibited 
in animal models is relevant in humans.
We observed differences in association depending on the type of contraceptive and progestin 
used. The agents in different hormonal contraceptives vary with respect to their biding 
affinities for androgen, progestogen, and estrogen receptors. Some exert androgenic 
properties, others anti androgenic properties.15 To our knowledge, studies of offspring 
adiposity or growth following exposure to progestogenic compounds during early fetal 
development have not been conducted in animals or humans. However, endogenous serum 
progesterone levels in pregnancy have been positively associated with offspring 
birthweight53, 54 and birthweight has been associated with offspring weight at follow-up.55 
Fetal exposure to androgenic agents has resulted in metabolic abnormalities, including a 
polycystic ovarian syndrome-like phenotype in animal models.12 Unopposed by ethinyl 
estradiol, desogestrel has high progestational and moderate androgenic activity relative to 
other progestin types, but when desogestrel is present in combination with ethinyl estradiol, 
the progestational and androgenic activities are substantively reduced.15 Norethisterone is 
only weakly androgenic. This property may explain the difference in association observed 
between desogestrel and norethisterone progestin-only contraceptives in this study.
The inverse association between use of the vaginal ring and offspring overweight or obesity 
may be attributable to the pharmacokinetic properties of the vaginal ring. The vaginal ring 
contains etonogestrel and ethinyl estradiol. Hormonal constituents of the vaginal ring are 
absorbed through the vaginal epithelium and provide steady release of etonogestrel and 
ethinyl estradiol for the three week period after the ring is inserted.15 Pharmacokinetic 
studies comparing the vaginal ring to the combination OC indicate that the dose of ethinyl 
estradiol, as measured in blood serum and represented by the area under the curve, is lower 
than that of doses experienced in combination OC users.56 The agents in the vaginal ring do 
not experience first pass metabolism. The ring provides a consistent release of hormones 
unaffected by dietary or gastrointestinal factors and is less subject to fluctuation in delivered 
dose when compared to oral or transdermal-administered forms of contraception.57
Sparse data limited the ability to assess variation in effects by different progestin types in 
early pregnancy. We found possible evidence of effect modification by offspring sex and 
maternal prepregnancy BMI for the combination OC; however, sample size limitations may 
have also precluded the ability to detect effect modification for the progestin-only 
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formulation. The possible effect modification observed for early pregnancy is consistent 
with animal data suggesting that developmental effects of estrogenic compounds may be 
stronger among male offspring.16 The associations observed could be attributable to residual 
confounding or confounding by indication. Women may be prescribed different 
contraceptive formulations based on factors for which we cannot control in our data. 
Notwithstanding, estimates obtained from sensitivity analyses, conducted to assess the 
potential for confounding by indication, were robust to choice of comparator group. Use of 
methods to explore the potential for bias from loss to follow-up is effective only insofar as 
we have correctly assumed that we were able to successfully impute missing values from the 
covariates in our imputation models (multiple imputation approach) or correctly predict the 
probability of staying in the study from the covariates in our predicted probability models 
for generating weights (inverse probability weighting approach). There was also a potential 
for misclassification of the timing of exposure.
The overall proportion of overweight or obese children at age 3 in this study (13.1%) is 
relatively consistent with national prevalence estimates for overweight or obesity at age 3 
that were obtained from height and weight data collected by research staff (11.3%).58 
Nonetheless, BMI is less specific for identifying clinically relevant adiposity in children 
when compared to other measures of assessing childhood adiposity.59
Overweight and obesity may be influenced by developmental exposure to exogenous sex 
hormones. The present data suggest that pharmacologic sex hormone agents may be 
associated with offspring overweight or obesity at age 3. The direction of the relationships 
appears contingent upon hormone formulation. Little is known about long-term, 
formulation-specific effects on offspring weight status.
Data from experiments on animals suggest that early life exposure to hormonally-active 
agents may affect offspring growth. Given the evidence that early life anthropometric 
indicators are associated with adult adiposity,2, 3 the investigation of determinants of early 
life anthropometrics is warranted. The results presented provide support for the assertion 
that in utero exposure to hormonally active agents, during developmentally sensitive 
periods, may contribute to alterations in offspring growth.
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Table 1
Study and baseline population characteristics among women participating in the Norwegian Mother Child 
Prospective Cohort Study (2004–2008)




















4 or more 0.9 0.8
Maternal education
More than 4 years of university or technical 27.2 29.9
4 year university degree, regional technical 40.8 43.9
3 years high school, junior college 13.5 12.0
Technical high school 11.2 9.3
1–2 years high school 3.9 2.6
9-year secondary 2.2 1.1
Other 1.4 1.4






Represents unique pregnancies with no use of IVF treatment, resulting in a singleton live birth and no death in the first year of life, with a date of 
birth ≥12 months after NorPD registry began (January 1, 2004)
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Table 2
Association between hormonal contraceptive use in early pregnancy* and offspring overweight or obese
Exposure Exposed (n)
Overweight or
obese (n) Crude OR (95% CI) Adjusted** OR (95% CI)
None† 9,987 1,342 referent referent
Combination OC 380 38 0.72 (0.51, 1.01) 0.75 (0.53, 1.08)
Progestin only OC 127 21 1.28 (0.80, 2.05) 1.26 (0.79, 2.02)
Other‡ 60 7 0.85 (0.39, 1.88) 0.88 (0.40, 1.94)
*
use within 12 weeks after conception as compared to no use of a hormonal contraceptive within the discrete categories of within 12, 4, and 1 
month before conception and within 12 weeks after conception
**
adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity
†
no use of a hormonal contraceptive within the discrete categories of within12, 4, and 1 month before conception and within 12 weeks after 
conception
‡
hormonal contraceptives with < 10 exposed cases were combined into an “other” category
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Table 3
Sensitivity analyses for early pregnancy exposure to hormonal contraceptives and offspring overweight or 
obesity
n OR (95% CI) Adjusted** OR (95% CI)
Approach 1: Compared to former users Combination OC
former* user of Combination OC 6,146 referent referent
*early pregnancy Combination OC user 380 0.76 (0.54, 1.07) 0.75 (0.52, 1.06)
Progestin only OC
former* user of Progestin OC 1,962 referent referent
*early pregnancy Progestin OC user 127 1.20 (0.74, 1.94) 1.24 (0.75, 2.04)
Approach 2: Compared to unplanned pregnancies
No hormonal contraception† 2,264 referent referent
Combination OC 380 0.67 (0.46, 0.96) 0.70 (0.48, 1.02)
Progestin only OC 127 1.19 (0.73, 1.93) 1.22 (0.75, 1.98)
Other‡ 60 0.79 (0.36, 1.76) 0.79 (0.35, 1.78)
Approach 3: Compared to other oral hormonal contraceptive users
Progestin only OC 127 referent referent
Combination OC 380 0.46 (0.23, 0.91) 0.56 (0.32, 1.00)
*
former use defined as within 12 months but not within 4 months of conception and early defined as within 12 weeks of conception
**
adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, education, and parity
†
no use of a hormonal contraceptive within 12 months before conception and 12 weeks after conception
‡
hormonal contraceptives with < 10 exposed cases were combined into an “other” category
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